EP1534272A2 - Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4 - Google Patents

Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4

Info

Publication number
EP1534272A2
EP1534272A2 EP03753390A EP03753390A EP1534272A2 EP 1534272 A2 EP1534272 A2 EP 1534272A2 EP 03753390 A EP03753390 A EP 03753390A EP 03753390 A EP03753390 A EP 03753390A EP 1534272 A2 EP1534272 A2 EP 1534272A2
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
rhinitis
mono
allergic rhinitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03753390A
Other languages
German (de)
English (en)
Inventor
Chris Rundfeldt
Hildegard Kuss
Norbert Höfgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elbion GmbH
Original Assignee
Elbion GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion GmbH filed Critical Elbion GmbH
Publication of EP1534272A2 publication Critical patent/EP1534272A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to the use of hydroxyindolyl-glyoxylic acid amides as inhibitors of phosphodiesterase 4 for the treatment of non-allergic rhinitis.
  • Non-allergic rhinitis is the term used to describe a whole range of diseases in which the symptoms of chronic rhinitis are involved, but which have no allergic origin.
  • the general symptoms of non-allergic rhinitis are nasal blockage / constipation and nasal flow without the symptoms of sneezing and conjunctivitis. Frequent sneezing and irritation of the conjunctiva are symptoms that mainly appear in allergic rhinitis.
  • Patients with non-allergic rhinitis have negative or clinically irrelevant allergic skin tests and normal serum IgE levels.
  • vasomotor rhinitis a chronic idiopathic disease that is not infectious, does not show elevated serum IgE levels, and is not associated with inflammation and / or eosinophilia. It is the most common form of non-allergic rhinitis with the main symptoms of constipation and nasal flow. The pathophysiology of this disease is unclear, the nasal hyperreactivity that occurs is not triggered by immunological stimuli such as cold air, cigarette smoke, chemical irritants, strong smell or physical exertion and stress (pointers, RS, allergy and nonallergic rhinitis. Classification and Pathogenesis: Part II. Nonallergic rhinitis, American Journal of Rhinology (1 989), 3: 1 1 3-139).
  • NARES Non-allergic rhinitis with eosinophil syndrome
  • Chronic sinusitis is a chronic non-bacterial inflammation of the mucous membrane.
  • Medicinal rhinitis is caused by a number of substances, such as beta blockers, ACE inhibitors, oral contraceptives or prazosin. It is characterized by interstitial edema rather than vasodilation. Nasal polyps occur frequently in chronic non-allergic rhinitis and exacerbate their symptoms (Pointer (1 989), supra).
  • non-allergic rhinitis occurs as a symptom of respiratory infections including the
  • Protozoa or higher-celled parasites are less common cause of rhinitis.
  • the infection ie the colonization with the germs mentioned, can be limited locally to the mucous membranes of the upper respiratory tract, as in the case of an infection with rhinoviruses, or, as in the case of the influenza virus infection, can affect the entire body in addition to the upper respiratory tract.
  • All of these Infections have in common that an inflammatory change in the nasal mucosa can be observed as a symptom. This can have a more exudative character (runny nose) or a more edematous character (swollen nose).
  • the majority of these infectious diseases are acute, but chronic courses are known. These chronic rhinitis, like other chronic (non-infectious) rhinitis, often lead to formation of the nasal mucosa, the so-called nasal polyps.
  • Allergic rhinitis also known as hay fever, differs significantly from the forms of non-allergic rhinitis. As with all allergic diseases, allergic rhinitis is based on a chronic, progressively complex, cellular inflammatory reaction, which is characterized by an accumulation of eosinophilic granulocytes and increased serum IgE levels. Allergic rhinitis is triggered by hypersensitivity to allergens such as pollen, house dust, mites, animal hair or chemical substances.
  • Some of these remedies may only be used for a short time, since tissue is destroyed during prolonged use (vasoconstrictors, eg alpha-adrenergic substances (Bachert, C, Ganzer, U., Nasal hyperreactivity, allergic rhinitis and its differential diagnoses - consensus report on pathophysiology, classification , Diagnosis and Therapy .; Nasal hyperreactivity. Allergy rhinitis and differential diagnoses - consens report on pathophysiology, classification, diagnosis and therapy Laryngo-rhino-otologie (1997), 72 (2): 65-76). It is known that selective inhibitors of the PDE4 isoenzyme can be used for the therapy of allergic rhinitis or allergic bronchial asthma.
  • vastrictors eg alpha-adrenergic substances (Bachert, C, Ganzer, U., Nasal hyperreactivity, allergic rhinitis and its differential diagnoses - consensus report on pathophysiology, classification , Diagnos
  • Cyclic adenosine monophosphate belongs to the so-called intracellular messenger substances, the intracellular concentration of which is regulated by the phosphodiesterase (PDE) isoenzyme. Studies have shown that selective inhibitors of the PDE4 isoenzyme increase the intracellular concentration of cAMP and thereby inhibit the pro-inflammatory activity of a large number of cells (eg eosinophilic and neutrophilic granulocytes).
  • Selective PDE4 inhibitors also inhibit the release of histamine from the mast cells or stabilize the endothelial cells of the blood vessels in the nasal mucosa, which means that these active compounds are also suitable for treating the acute symptoms of allergic rhinoconjunctivitis (Barnette, MS, phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD).
  • PDE4 inhibitors Progress Drug Research (1999), 53, E. Jucker Ed., Birkhäuser Verlag, Basel (Switzerland); Dyke, HJ and Montana, JG, The therapeutic potential of PDE4 inhibitors, Exp Opin Invest Drugs, (1999), 8 (9): 1301-1325).
  • a particularly preferred compound is the compound N- (3,5-dichloropyrid-4-yl) - [1 - (4-fluorobenzyl) -5-hydroxy-indol-3-yl] glyoxylic acid amide (AWD 12-281).
  • a particularly preferred compound is the compound N- (3,5-dichloropyrid-4-yl) - [1 - (4-fluorobenzyl) -5-hydroxy-indol-3-yl] glyoxylic acid amide (AWD 12-281).
  • These hydroxyindolyl-glyoxylic acid amides can be used to treat inflammatory respiratory diseases such as allergic rhinitis.
  • AWD 12-322 N- (3,5-dichloropyrid-4-yl) -2- [5-hydroxy-1 - (4-hydroxybenzyl) -1 H-indol-3-yl] glyoxylic acid amide
  • AWD 12-298 N- (3,5-dichloropyrid-4-yl) - [1 - (2,6-difluorobenzyl) -5-hydroxyindol-3-yl] glyoxylic acid amide semi-ethyl acetate).
  • Standard drugs for this form of disease are steroids, such as Beclomethasone or anticholinergics such as ipratropium bromide.
  • steroids such as Beclomethasone or anticholinergics such as ipratropium bromide.
  • anticholinergics such as ipratropium bromide.
  • Vasomotor rhinitis is one of the most common forms of non-allergic rhinitis. Excessive water rhinorrhea is triggered in patients by parasympathetic hyperreactivity by stimulating or toxic parasympathetic nerves of the nasal mucosa be irritated. Likewise, substances that greatly expand the blood vessels can trigger strong nasal flow and edema of the mucous membranes.
  • this non-allergic form of increased nasal flow can be triggered by the action of acetic acid on the nasal mucosa of the animals.
  • the appearance of increased aqueous rhinitis after exposure to acetic acid is triggered by two causes. Inhaled acetic acid vapor or the superfusion of the nasal mucosa with acetic acid on the one hand triggers an immediate dilation of the blood vessels of the nasal mucosa, which leads to a strong vascular permeability.
  • acetic acid can increase the parasympathetic activity of the sensory nerve fibers in the nasal mucosa.
  • acetic acid Chemical substances with a strong odor, such as acetic acid, also stimulate the parasympathetic activity of the nasal glands in a nervous-reflex manner, so that there is an overproduction of watery secretions and thus an increased nasal flow.
  • acetic acid on mucous membranes is toxic and leads to a loss of adenosine triphosphate (ATP) in the tissue cells.
  • ATP adenosine triphosphate
  • the invention relates to the use of hydroxyindol-3-yl-glyoxylic acid amides of the formula (I)
  • R 1 is -CC 6 -alkyl, straight-chain or branched-chain, saturated or partially unsaturated, is optionally mono- or polysubstituted with mono-, bi- or tricyclic saturated or mono- or poly-unsaturated carbocycles with 3-14 ring members or mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-1 5 ring members and 1-6 heteroatoms, which are preferably N, O and S, the carbocyclic and heterocyclic substituents in turn optionally being mono- or polysubstituted with -OH, - SH, -NH 2 , -NHC C 6 -alkyl, -N (C 1 -C 6 -alkyl) 2 , -NHC 6 -C 14 aryl, -N (C 6 -C 14 aryl) 2 , -N (C 1 -C 6 alkyl) (C 6 -C 14 aryl), -NO 2 ,
  • R 2 , R 3 represents hydrogen or -OH, at least one of the two substituents being -OH;
  • R 4 represents a mono- or polycyclic aromatic carbocycle with 6-14 ring members or a mono- or polycyclic heterocycle with 5-15 ring members, the heteroatoms being selected from N, O and S, optionally substituted one or more times with -F , -Cl, - Br, -I, -OH, - SH, -NH 2 , -NH (C r C 6 alkyl), -N (CC 6 alkyl) 2 , -NH (C 6 -C 14 aryl ), -N (C 6 - C 14 aryl) 2 , -N (C r C 6 -alkyl) (C 6 -C 14 aryl), -NO 2 , -CN, -OC r C 6 -alkyl, - OC 6 - C 14 -aryl, -C r C 6 -alky
  • R 1 is preferably an optionally substituted C j -CG alkyl, such as n-propyl, isopropyl, cyclopentylmethyl or a benzyl radical, which in turn mono- or polysubstituted by halogen, such as -F, -OC r C 6 alkyl or -0- C, -C 6 - haloalkyl, for example -OCH 3 or OCF 3 , or / and -C r C 6 -alkyl or C r C 6 - haloalkyl, for example -CH 3 or -CF 3, may be substituted.
  • halogen such as -F, -OC r C 6 alkyl or -0- C, -C 6 - haloalkyl, for example -OCH 3 or OCF 3 , or / and -C r C 6 -alkyl or C r C 6 - haloalkyl, for example -CH 3 or
  • R 4 preferably represents mono- or bicyclic aromatic carbocycles or heterocycles.
  • R 4 particularly preferably represents phenyl or pyridyl, in particular 4-pyridyl.
  • R 4 is mono- or polysubstituted with -F, -Cl, -Br or / and I. Most preferred is the compound AWD12-281.
  • AWD 12-322 N- (3,5-dichloropyrid-4-yl) -2- [5-hydoxy-1 - (4-hydoxybenzyl) -1 H -indole-3- yl] - glyoxylic acid amide
  • AWD 12-298 N- (3,5-dichloropyrid-4-yl) - [1 - (2,6-difluorobenzyl) -5-hydroxy-indol-3-yl] glyoxylic acid amide -Semi-acetate.
  • pharmacologically acceptable salts thereof can also be used.
  • the pharmacologically acceptable salts can be obtained by neutralizing the compounds with suitable organic or inorganic bases or acids.
  • Compounds of formula (I) can be used for therapeutic treatment and / or prevention of various forms of non-allergic rhinitis, e.g. vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, chronic sinusitis, medicinal rhinitis and other forms of non-allergic rhinitis.
  • non-allergic rhinitis e.g. vasomotor rhinitis, non-allergic rhinitis with eosinophilia syndrome, chronic sinusitis, medicinal rhinitis and other forms of non-allergic rhinitis.
  • the compounds according to the invention are preferably administered in the form of pharmaceutical compositions which, in addition to the active ingredient, contain pharmacologically acceptable carriers, auxiliaries or diluents.
  • the dosage of the active ingredients can vary depending on the route of administration, age, weight of the patient, type and severity of the diseases to be treated and similar factors.
  • the daily dose can be given as a single dose to be administered once or divided into two or more daily doses and is usually 0.001 to 100 mg, e.g. 0.01 to 50 mg.
  • application forms come e.g. oral, parenteral, intravenous, transdermal, topical, inhalative and intranasal preparations in question, with inhalative and intranasal preparations being preferred.
  • galenical forms of preparation such as tablets, dragees, capsules, dispersible powders, granules, aqueous solutions, aqueous or oily suspensions, syrups, juices or
  • Drops It is particularly preferably administered in the form of atomized liquid preparations, for example in the form of aerosols or sprays.
  • the compounds according to the invention or pharmaceutical preparations containing these compounds can also be used in combination with other pharmacological active ingredients, e.g. anti-inflammatory preparations, e.g. Corticosteroids (steroids) (e.g. beclomethasone) or leukotriene antagonists (e.g. montelukast), secretion inhibitors, e.g. Anticholinergics (e.g. ipratropium bromide), antihistamines, e.g. Azelastine, vasoconstrictors such as e.g. Xylometazoline hydrochloride, antiviral drugs, such as Oseltamivir or Adamantan, antibacterial preparations such as antibiotics (e.g. penicillin) or antifungal (fungicidal or fungistatic) preparations.
  • anti-inflammatory preparations e.g. Corticosteroids (steroids) (e.g. beclomethasone) or leukotriene antagonists (e.g
  • the invention is further illustrated by the following example.
  • a polyethylene infusion line is connected to the LUER-Lok connector of the retrograde catheter and immersed in the container with the prepared perfusion liquid via a roller pump.
  • the roller pump is set to the constant advance of 0.5 ml liquid / min.
  • a red light lamp for warming is switched on above the animals.
  • test substances are applied topically before the application of acetic acid. They are added to the perfusion medium (PBS, Dulbecco) in molar concentrations.
  • PBS perfusion medium
  • 5.2 mg of beclomethasone are treated with 2 ml of 1N NaOH and 4 ml of 96% ethanol in an ultrasound bath for 2 minutes and then bidistilled with H 2 O. Make up to 10 ml and add PBS to the final concentration.
  • ipratropium bromide 1.4 mg are diluted with 1 ml of 1 N NaOH and then bidistilled with H 2 O. Make up to 10 ml and add PBS to the final concentration. These solutions are run through the roller pump for 30 min Perfused noses, the 2 samples collected from the fraction collector are discarded. Then the roller pump is switched off.
  • the plasma marker Evans Blue (1% solution in PBS) 1 ml / animal is injected into the jugular vein and then 0.1% acetic acid solution is pressed into the nasal cavity via tubes and roller pumps until 2-3 Drip drops of acetic acid solution out of the turbinates. The roller pumps are then switched off. The acetic acid solution remains in the nasal cavity for 30 minutes to ensure complete penetration of the nasal mucosa.
  • the roller pumps and the fraction collector are switched on again and the 0.1% acetic acid solution in PBS is retrograded through the nasal cavity for 60 minutes (with constant propulsion of 0.5 ml liquid / min).
  • the perfusate dripping from the nostrils is continuously taken up in glass tubes and collected at 4 intervals of 15 minutes. Aliquots of the samples, including the normal value samples, are applied to microtiter plates and measured with the Digiscan photometer at a wavelength of 620 nm relative to the normal value sample (blank).
  • AUC area under the curve, AUC 0 - 60 m i n 'n / ⁇ / D calculated (Grunwald, C, AUC 1 .0, calculation and graphic representation of "Area Under Curve "(AUC) values, internal report of Arzneistofftechnikmaschinee Dresden GmbH, Aug. 1 995).
  • the Evans Blue content in the outflowing perfusate in / g / ml in 4 fractions of 15 minutes each is calculated according to Formula 1:
  • AUC ' 0 . 60 min AUC 0 . 60 min - basal value x 60 min
  • the mean values and standard deviations (x ⁇ SD) of the AUC of individual animals in a control group or an animal group pretreated with substance are calculated.
  • the inhibition of vascular permeability is given in percent.
  • the calculation is carried out by setting the mean dye content of the pooled fractions of vehicle treated control animals as 100% and comparing the average dye content of the pooled fractions of animals that have been treated prophylactically with substance (x% inhibition). Each substance concentration and each corresponding vehicle solution is tested on 4 to 8 animals.
  • AUC "Area Under Curve” value considering the basal value n number of animals per group
  • AUC "Area Under Curve” value considering the basal value n number of animals per group
  • AUC "Area Under Curve” value considering the basal value n number of animals per group
  • AUC "Area Under Curve” value considering the basal value n number of animals per group
  • AUC "Area Under Curve” value considering the basal value n number of animals per group
  • the selective PDE4 inhibitors AWD 12-281 and 12-322 show a concentration-dependent inhibition of the vascular permeability of the nasal mucosa in the test range from 0.1 to 10 ⁇ mol / l using the rat acetic acid-induced rhinitis model.
  • the derivative AWD 12-298 is in the Concentration range of 3 to 10 // mol / l effective depending on the concentration.
  • the standard therapeutic agents for the treatment of non-allergic rhinitis such as the corticosteroid beclomethasone and the anticholinergic ipratropium bromide, are approximately equally effective.
  • the inhibition of plasma extravasation induced by acetic acid by PDE4 inhibitors is a completely unexpected and novel finding that has not yet been described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'amides d'acides hydroxyindolyl-glyoxyliques en tant qu'inhibiteurs de phosphodiestérase-4 destinés au traitement de la rhinite non allergique.
EP03753390A 2002-09-06 2003-09-05 Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4 Withdrawn EP1534272A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10241407A DE10241407A1 (de) 2002-09-06 2002-09-06 Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe
DE10241407 2002-09-06
PCT/EP2003/009895 WO2004022041A2 (fr) 2002-09-06 2003-09-05 Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4

Publications (1)

Publication Number Publication Date
EP1534272A2 true EP1534272A2 (fr) 2005-06-01

Family

ID=31724458

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753390A Withdrawn EP1534272A2 (fr) 2002-09-06 2003-09-05 Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4

Country Status (18)

Country Link
US (1) US20040116501A1 (fr)
EP (1) EP1534272A2 (fr)
JP (1) JP2005539058A (fr)
KR (1) KR20050034760A (fr)
CN (1) CN1678307A (fr)
AR (1) AR041172A1 (fr)
AU (1) AU2003271586A1 (fr)
BR (1) BR0314031A (fr)
CA (1) CA2497374A1 (fr)
DE (1) DE10241407A1 (fr)
HR (1) HRP20050310A2 (fr)
MX (1) MXPA05002437A (fr)
NO (1) NO20051468L (fr)
PL (1) PL375494A1 (fr)
RU (1) RU2005109939A (fr)
TW (1) TW200404777A (fr)
WO (1) WO2004022041A2 (fr)
ZA (1) ZA200501582B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670787B1 (fr) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Inhibiteurs des cytokines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701682A (nl) * 1986-07-30 1988-02-16 Sandoz Ag Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE19818964A1 (de) * 1998-04-28 1999-11-04 Dresden Arzneimittel Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004022041A2 *

Also Published As

Publication number Publication date
HRP20050310A2 (en) 2005-06-30
TW200404777A (en) 2004-04-01
NO20051468L (no) 2005-06-03
ZA200501582B (en) 2005-09-09
AR041172A1 (es) 2005-05-04
BR0314031A (pt) 2005-07-05
PL375494A1 (en) 2005-11-28
WO2004022041A2 (fr) 2004-03-18
WO2004022041A3 (fr) 2004-05-06
JP2005539058A (ja) 2005-12-22
CN1678307A (zh) 2005-10-05
AU2003271586A1 (en) 2004-03-29
MXPA05002437A (es) 2005-06-03
DE10241407A1 (de) 2004-03-18
US20040116501A1 (en) 2004-06-17
RU2005109939A (ru) 2005-09-10
KR20050034760A (ko) 2005-04-14
CA2497374A1 (fr) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60026855T2 (de) Synergistische kombination von roflumilast und salmeterol
EP1265615B1 (fr) Nouvelle combinaison d'antihistaminiques non sedatifs et de substances qui influencent l'effet du leucotriene, pour le traitement de la rhinite/conjonctivite
EP2214658B1 (fr) Préparation contenant des osmolytes destinée à être employée en cas de muqueuses sèches
DE60119534T2 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
DE60121301T2 (de) Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen
DE69113386T2 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
DE60209511T2 (de) Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
US9186360B2 (en) Treatment of respiratory disorders using TRPA1 antagonists
EP2380569B1 (fr) Osmolyte à la reduction des effects secondaires des steroïdes ou antihistaminiques
WO2008148573A2 (fr) Médicaments contenant une combinaison de principes actifs pour traiter les symptomes allergiques
WO2004019984A1 (fr) Nouvelle combinaison de glucocorticoides et d'inhibiteurs de pde-4 pour traiter des maladies des voies respiratoires, des maladies allergiques, de l'asthme et des maladies pulmonaires chroniques obstructives
WO2012176105A1 (fr) Composition pharmaceutique comprenant un antagoniste du trpa1 et un antagoniste du récepteur de leucotriènes
WO2017046312A1 (fr) Composition à effet antiviral
EP1534272A2 (fr) Traitement de la rhinite non allergique au moyen d'inhibiteurs selectifs de phosphodiesterase-4
EP2818167A1 (fr) Composition pharmaceutique antivirale active
EP0876144B1 (fr) Agents therapeutiques contenant ebselen, agissant contre l'asthme
JP2015500278A (ja) Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物
DE202006005924U1 (de) Zusammensetzung zur Behandlung von Rhinitis
TR2023017339A2 (tr) Adenoi̇d vejetasyon, tekrarlayan seröz oti̇t ve alerji̇k ri̇ni̇t hastaliğinda i̇laç tedavi̇si̇ndekullanilmak üzere geli̇şti̇ri̇len kompozi̇syon
DE3231571A1 (de) Arzneipraeparat als stimulator der nervmuskeluebertragung, der glatten muskel, der erregungsleitung in dem peripherischen und zentralnervensystem
WO2014072380A1 (fr) Utilisation de nad et ss-nad comme bronchodilatateur
AU2012269972A1 (en) Treatment of respiratory disorders using TRPA1 antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050211

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1071850

Country of ref document: HK

RAX Requested extension states of the european patent have changed

Extension state: MK

Payment date: 20050211

Extension state: LV

Payment date: 20050211

Extension state: LT

Payment date: 20050211

17Q First examination report despatched

Effective date: 20060817

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061228

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1071850

Country of ref document: HK